Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lifirafenib maleate by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Lifirafenib maleate by BeiGene for Ovarian Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Lifirafenib maleate by BeiGene for Solid Tumor: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Lifirafenib maleate by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Lifirafenib maleate by BeiGene for Ovarian Cancer: Likelihood of Approval
Lifirafenib maleate is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...